NewEut®. Treatment of hemophilia

July 04, 2016
Active substances:
Trade names:
ICD-10:
III.D65-D69.D68.2    Hereditary deficiency of other coagulation factors
Novoate, turrotokog alpha, hemophilia, treatment of hemophilia, factor VIII
In June 2016, Novo Nordisk A / S registered a drug for the treatment of haemophilia A-NovoEyt® on the territory of the Russian Federation.
Complete official instruction of the state register of medicines to the commercial drug NewEut® read in the TALKDRUGS medicinal guide here.
The drug is a coagulation factor VIII (turrotokog), the amount of which determines the severity of the course of hemophilia A. The mechanism of action is associated with an increase in the level of factor VIII in blood plasma.
Used to prevent and control bleeding in patients with hemophilia, including surgical procedures.
According to the results of clinical studies, the effectiveness of NovoEth® in the treatment and prevention of bleeding in patients with severe hemophilia A.
Not applicable for the treatment of a disease Willebrand.